United States securities and exchange commission logo





                            October 13, 2022

       Quang Pham
       Chief Executive Officer
       Cadrenal Therapeutics, Inc.
       822 A1A North, Suite 320
       Ponte Vedra, FL 32082

                                                        Re: Cadrenal
Therapeutics, Inc.
                                                            Amendment No. 1 to
Registration Statement on Form S-1
                                                            Filed October 11,
2022
                                                            File No. 333-267562

       Dear Quang Pham:

            We have reviewed your amended registration statement and have the
following
       comment.

              Please respond to this letter by amending your registration
statement and providing the
       requested information. If you do not believe our comment applies to your
facts and
       circumstances or do not believe an amendment is appropriate, please tell
us why in your
       response.

              After reviewing any amendment to your registration statement and
the information you
       provide in response to this comment, we may have additional comments.

       Amendment No. 1 to Registration Statement on Form S-1

       Public Offering Prospectus Summary
       Our Business, page 1

   1.                                                   Please balance your
disclosure regarding the tecarfarin patents on pages 3 and 69
                                                        with additional
disclosure that you have not engaged intellectual property counsel
                                                        to conduct a freedom to
operate analysis and briefly explain how this impacts your
                                                        certainty regarding
your claims to the tecarfarin patents.
              You may contact Ibolya Ignat at 202-551-3636 or Al Pavot at
202-551-3738 if you have
       questions regarding comments on the financial statements and related
matters. Please contact
       Dillon Hagius at 202-551-7967 or Jason Drory at 202-551-8342 with any
other questions.
 Quang Pham
Cadrenal Therapeutics, Inc.
October 13, 2022
Page 2
                                           Sincerely,
FirstName LastNameQuang Pham
                                           Division of Corporation Finance
Comapany NameCadrenal Therapeutics, Inc.
                                           Office of Life Sciences
October 13, 2022 Page 2
cc:       Leslie Marlow
FirstName LastName